NeuroPace (NPCE) Cash & Equivalents Growth (1y) (2021 - 2026)
NeuroPace (NPCE) Cash & Equivalents Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 4.15% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 24.05% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -12.13% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 100.41% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -22.13% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 23.57% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -7.71% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | -10.02% |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 141.82% |
| 10 | NeuroPace | 517.05 Mn | 463.07 Mn | 18.05 Mn | -45.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.30% |
| Dec 31, 2025 | 61.52% |
| Sep 30, 2025 | 33.92% |
| Jun 30, 2025 | 77.96% |
| Mar 31, 2025 | 107.87% |
| Dec 31, 2024 | -25.63% |
| Sep 30, 2024 | 58.67% |
| Jun 30, 2024 | 63.51% |
| Mar 31, 2024 | 93.42% |
| Dec 31, 2023 | 173.40% |
| Sep 30, 2023 | 70.83% |
| Jun 30, 2023 | 37.76% |
| Mar 31, 2023 | -10.27% |
| Dec 31, 2022 | -65.58% |
| Sep 30, 2022 | -78.64% |
| Jun 30, 2022 | -81.75% |
| Mar 31, 2022 | -45.89% |
| Dec 31, 2021 | -27.29% |
| Sep 30, 2021 | -38.26% |
| Jun 30, 2021 | 212.50% |